Abstracts tagged "Adenosine receptors and rheumatoid arthritis (RA)"

Abstract Number: 949 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study
Rumen M. Stoilov¹, Rodina N. Licheva², Mariyana K. Mihaylova³, Tatiana Reitblat⁴, Emil A. Dimitrov¹, Krasimira M. Shimbova¹, Girish Bhatia⁵, Amit Pispati⁶, Alexandra Gurman- Balbir⁷, B R Bagaria⁵, Boytcho A. Oparanov², Sari Fishman⁸, Zivit Harpaz⁸, Motti Farbstein⁸, Shira Cohen⁸, Michael H. Silverman⁸ and Pnina Fishman⁸, ¹Multiprofile Hospital for Active Treatment “Sv. Ivan Rilski” - EAD, Clinic of Rheumatology, Sofia, Bulgaria, ²Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ³3Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ⁴Barzilai Medical Center,, Ashkelon, Israel, ⁵Malpani Multispeciality Hospital, mumbai, India, ⁶Bhatia Hospital Medical Research Society, mumbai, India, ⁷Rambam Medical Center, Haifa, Israel, ⁸CanFite Biopharma Ltd, Petah Tikva, Israel
Background/Purpose: CF101, is a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and anti-inflammatory effect in Phase 2 clinical studies of rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.